Literature DB >> 20518407

Cytodiagnosis of extramedullary plasmacytomas.

Garima Goel1, Sharada Rai, Ramadas Naik, Astha Gupta, Poornima Baliga, Ruchi Sinha.   

Abstract

OBJECTIVE: Extramedullary plasmacytoma (EMP) constitutes approximately 4% of all plasma cell neoplasms. It may present as the sole manifestation of plasma cell neoplasm, as a solitary plasmacytoma of the bone or as a consequence of multiple myeloma. This study was done to determine the role of fine needle aspiration cytology (FNAC) in the diagnosis of EMP. STUDY
DESIGN: In our study 8 cases of EMP at various sites were diagnosed on FNAC. In 3 patients EMP was the initial presentation of plasma cell neoplasm. In the remaining 5 patients the tumors occurred during the course of treatment for multiple myeloma.
RESULTS: The lesions were located at various anatomic sites, including lymph node, scalp, breast, jaw, rib, clavicle and soft tissue swelling in the retrosternal region. The smears prepared from the aspirates in all cases revealed numerous plasma cells at various stages of maturation, leading to a diagnosis of EMP. Radiologic and bone marrow findings also substantiated the diagnosis of multiple myeloma in all but 1 case.
CONCLUSION: FNAC offers a rapid, reliable and accurate diagnosis of EMP and thus allows initiation of appropriate treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20518407     DOI: 10.1159/000325031

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Solitary plasmacytoma of the rib: A rare case.

Authors:  Rikki Singal; Usha Dalal; Ashwani Kumar Dalal; Ashok Kumar Attri; Samita Gupta; Rachna Raina
Journal:  Lung India       Date:  2011-10

2.  Cytodiagnosis of multiple myeloma presenting as chest wall swellings.

Authors:  Madhusmita Jena
Journal:  J Cytol       Date:  2012-04       Impact factor: 1.000

3.  Rare solitary neoplasm of the costa in an adult: a case report.

Authors:  Cheng Shen; Yasha Liang; Huan Xu; Guowei Che
Journal:  World J Surg Oncol       Date:  2014-09-25       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.